BAYER AG NA
Commented by André Will-Laudien on September 25th, 2024 | 07:00 CEST
The biotech rally of the century is on the horizon! 150% returns with BioNTech, Pfizer, Nyxoah, Bayer, or Evotec?
The stock market keeps climbing, and now it is moving even faster with a double-whammy interest rate cut from the Fed! In a surprising move, the US Federal Reserve pulls a 0.5% rate cut from its magic hat, boosting market sentiment. Now, it is certain that life will continue in the biotech sector. However, selecting the right stocks remains challenging. With a medium-term focus, paying attention to management quality is important because the recent price declines were too high in some cases. However, some research approaches promise a better future. BioNTech, Pfizer, and Bayer have already bottomed out. Nyxoah and Evotec are now showing the first signs of breaking out after a period of consolidation. What is the short-term outlook?
Read
Commented by André Will-Laudien on September 16th, 2024 | 07:15 CEST
This is unbelievable! 250% with an announcement: Bayer, Vidac Pharma, Evotec, and Valneva
The stock market has been rallying week after week, yet the biotech sector stubbornly lags behind. However, with the first interest rate cut in Europe, the path of lower financing options has now also been mapped out for the US. This week, the FED is set to decide on rate cuts, with 87% of capital market experts expecting a total of three cuts by the end of the year. That would be grist to the mill for growth stocks. Vidac Pharma has already gained 50% in 2 months, and Bayer and Evotec will likely follow soon. Valneva is raising EUR 61 million and aims to break even operationally. What is next for the sector?
Read
Commented by Fabian Lorenz on September 11th, 2024 | 07:00 CEST
Multiplication and travel boom! Bayer, TUI, Vidac Pharma
Vidac Pharma shares have gained over 23% in the past four weeks. Driven by strong study data from the biotech company focused on fighting cancer, analysts even see the potential for multiplication. Such euphoria has been absent at Bayer for some time. However, at least there is positive momentum from the pharmaceuticals division again, which is much needed, as the Leverkusen-based company's pipeline is considered modest. In contrast, business at TUI is booming. Nevertheless, the tourism group's shares have disappointed in the current year. Will a new cruise ship take it towards EUR 10?
Read
Commented by Armin Schulz on September 4th, 2024 | 07:30 CEST
Bayer, Vidac Pharma, BioNTech - Healthcare sector on the verge of a renaissance
Promising signs of a renaissance in the healthcare sector have emerged in recent months. Innovative start-ups are driving the digital transformation forward despite a decline in investment, as evidenced by the Digital Health Radar 2024. In Germany, Federal Health Minister Karl Lauterbach has introduced significant legislative reforms by July 2024, such as the introduction of electronic patient records and e-prescriptions. Complemented by increased M&A activity and technological integration through telehealth and AI, experts anticipate significant long-term growth potential despite the challenges faced in 2023. These developments point to a promising future for the healthcare sector. We take a look at three exciting candidates.
Read
Commented by André Will-Laudien on August 28th, 2024 | 07:00 CEST
Starting signal for a rally? BioNTech, Pfizer, and Bayer under scrutiny, Major news expected from Cardiol Therapeutics and Evotec
Despite all the prophecies of doom, life goes on in the biotech sector. With a medium-term focus, it makes sense to bet on management qualities, as the recent price drops were partially too severe, but the research approaches promise a better future. BioNTech and Pfizer still have to deal with the COVID-19 issue, while Bayer has now taken all measures to achieve a turnaround. The situation at Cardiol Therapeutics and Evotec is particularly interesting, as the members of the Management Board continue to buy shares regularly.
Read
Commented by Armin Schulz on August 21st, 2024 | 07:00 CEST
Bayer, Cardiol Therapeutics, Evotec - Is monkeypox providing new momentum in the biotech and pharma sector?
The recent outbreak of monkeypox has once again highlighted the critical importance of a rapid and effective response to emerging health threats. This situation highlights the significant role of the biotech and pharmaceutical industries in addressing such challenges. Some companies are focused on combating infectious diseases such as monkeypox, while others are developing innovative therapies for chronic, severe, or rare diseases. Today, we look at three companies committed to improving people's health.
Read
Commented by André Will-Laudien on August 5th, 2024 | 07:00 CEST
In the fight against cancer - 100% performance possible: Bayer, Vidac Pharma, Evotec, BioNTech and CureVac
The FED is giving new hope to the Biotech sector with lower interest rates, which are expected to happen as early as September. This is important for the near future, as share prices are lagging dramatically behind the NASDAQ performance in 2024. However, if extensive research can be financed under more favourable conditions, this should also help the stock market prices recover. The business models contain some good news, and selection is now crucial. We assist in selecting attractive stocks and provide entry levels.
Read
Commented by Fabian Lorenz on August 1st, 2024 | 06:30 CEST
Evotec slashed, Bayer sued, and Cardiol Therapeutics share praised
Anyone speculating on a quick rebound for Evotec will be disappointed. At present, one can at most speak of a bottoming out. It is fitting that a renowned analyst has slashed his price target for the German biotech share. Or is it only half as bad? Analysts see massive upside potential for the shares of Cardiol Therapeutics. The share price has more than doubled in the current year and is currently consolidating. There is an exciting entry opportunity now that positive study results have fizzled out on the stock market. Bayer, on the other hand, simply cannot get out of the world's courtrooms. In the US, a new lawsuit has been filed against the Leverkusen-based company; in another case, a multi-million dollar payment must be made.
Read
Commented by André Will-Laudien on July 25th, 2024 | 08:20 CEST
BioNTech, CureVac, Bayer, Cardiol Therapeutics, and Evotec: Tripled and still in turbo mode?
On the stock market, separating the wheat from the chaff is essential, especially in the biotech sector. This task becomes challenging when ongoing studies conclude, and their results must be interpreted. The market does not always react correctly to announcements, as evidenced by this year's acquisition of MorphoSys. While the stock market rejected the supposedly poor results, Novartis built up the first favourable positions, ultimately acquiring the Munich-based company for EUR 2.7 billion. From a low of around EUR 12, the acquisition price was a high EUR 68, making it a 500% deal. But opportunities are always lurking. Here is a selection of promising candidates.
Read
Commented by Fabian Lorenz on July 24th, 2024 | 06:30 CEST
BioNTech, Bayer, Vidac Pharma: Buy recommendations and potential worth billions
Can BioNTech shares stop the downward trend? A "Buy" recommendation gives hope. According to this recommendation, the shares of the German biotech flagship have the potential to double in value. Analysts believe a multiplication is possible for Vidac Pharma. The biotech company is pursuing a revolutionary approach in the fight against cancer, and the first drug has a revenue potential of over EUR 1 billion. Even though research is still ongoing, Vidac is not expensive with a market capitalization of less than EUR 10 million, and is a takeover candidate if the study data remain positive. Analysts do not currently see any impetus for an increase in Bayer's share price. However, shareholders should be ready for news from the pharmaceutical pipeline in the coming weeks. These are important for the DAX-listed company.
Read